Oncology Institute (TOIIW) Receivables - Other (2020 - 2026)

Oncology Institute has reported Receivables - Other for 7 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 280.35% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 280.35% YoY), and the FY2025 full-year result was $322000.0, down 6.94% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.3 million, up from $322000.0 in the prior quarter.
• The five-year high for Receivables - Other was $1.3 million in Q1 2026, with the low at $276000.0 in Q2 2025.
• Historically, Receivables - Other has averaged $520000.0 across 5 years, with a median of $422000.0 in 2022.
• Annual changes were most pronounced in 2023 — Receivables - Other sank 66.54% — and 2026, when it surged 280.35%.
• Oncology Institute's Receivables - Other stood at $617000.0 in 2022, then declined by 10.7% to $551000.0 in 2023, then sank by 37.21% to $346000.0 in 2024, then declined by 6.94% to $322000.0 in 2025, then surged by 308.7% to $1.3 million in 2026.
• The last three Receivables - Other figures came in at $1.3 million (Q1 2026), $322000.0 (Q4 2025), and $339000.0 (Q3 2025), per Business Quant data.